-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)
StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)
Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Acorda Therapeutics Price Performance
Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.
Get Acorda Therapeutics alerts:Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.
Institutional Trading of Acorda Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the 2nd quarter valued at $28,000. Virtu Financial LLC purchased a new position in Acorda Therapeutics during the second quarter valued at $68,000. Millennium Management LLC grew its holdings in Acorda Therapeutics by 661.2% in the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 270,588 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company's stock.About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com的股票研究人员在周一发布的一份报告中假设了阿科达治疗公司(纳斯达克:ACOR-GET Rating)的股票报道。该经纪公司对这家生物制药公司的股票设定了“持有”评级。
Acorda Therapeutics Price Performance
Acorda治疗公司的性价比
Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.
周一,ACOR股票开盘报0.29美元。该公司市值为706万美元,市盈率为-0.03,贝塔系数为0.45。该公司的速动比率为1.49,流动比率为1.86,债务权益比为2.10。该业务的50日简单移动均线为0.42美元,200日简单移动均线为0.77美元。Acorda Treeutics的12个月低点为0.28美元,12个月高位为4.94美元。
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.
阿科达治疗公司(纳斯达克:ACOR-GET评级)上一次公布季度收益数据是在8月4日星期四。这家生物制药公司公布了本季度每股收益(2.78美元),低于普遍预期的(0.36美元)和(2.42美元)。阿科达治疗公司的净资产回报率为负90.29%,净利润率为负98.25%。该公司本季度的收入为3105万美元。
Institutional Trading of Acorda Therapeutics
Acorda Treateutics的机构交易
About Acorda Therapeutics
关于阿科达治疗公司
(Get Rating)
(获取评级)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治疗公司是一家生物制药公司,在美国开发和销售神经疾病的治疗方法。该公司在欧洲营销Ampyra(达法普利定),一种改善多发性硬化症(MS)患者行走能力的口服药物;以及Inbrija,用于治疗帕金森病的间歇期。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免费获取StockNews.com关于Acorda治疗公司(ACOR)的研究报告
- 防御性股票应对动荡的市场
- SunPower准备推动三位数的收益增长
- UPS会成为下一个发出警告的公司吗?
- 这是Gap Stock黎明前最黑暗的一次吗?
- 与捷普公司一起打造更好的技术产品组合。
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acorda治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acorda Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧